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Previewsa-Gal-A enzyme activity. Therefore, these
findings suggested that microbial activa-
tion of DCs leads to an accumulation of
glycolipids that are normally degraded
by a-Gal-A (Figure 1, right panel). Inhibitor
studies further suggested that iGb3 could
well be a relevant glycolipid in this
context.
The idea that iGb3 might be the sole
antigen that controls the intrathymicdevel-
opment of iNKTcells is particularly conten-
tious (Gapin, 2010). Darmoise et al. (2010)
were unable to identify a defect in intrathy-
mic development of iNKT cells in Fabry
mice, which is consistent with some, but
not all, prior studies (e.g., Gadola et al.,
2006). Nevertheless, they found that
numbers of peripheral iNKT cells in these
animals were substantially suppressed,
which they attributed to increased death
because of chronic activation in the
periphery. Consistent with this possibility,
the remaining iNKT cells in Fabry mice ex-
hibited a hyporesponsive phenotypewhen
stimulated with a-galactosylceramide,
which was associated with increased
expression of inhibitory NK cell receptors.
Is this pathway for the generation of
endogenous iNKT cell antigens in mice
conserved in humans? Probably not.
Studies with human iNKT cell clones
have failed to find a role for the CD1drecycling pathway (see Figure 1) in the
autoreactivity of these cells (Chen et al.,
2007). Further, as mentioned above,
although ultrasensitive mass spectrom-
etry studies were able to identify iGb3 in
human thymus, the iGb3 synthase gene
in humans appears to be defective. Lastly,
patients with Fabry disease have normal
numbers of iNKT cells.
As with most provocative studies, the
paper from Darmoise et al. (2010) raises
more questions than it answers: What are
the relevant iNKT cell self-antigens that
accumulate in Fabrymice? Is the accumu-
lation of iNKT cell antigens in Fabry mice
unique to DCs, or does this also occur in
other cell types such as the cells that
mediate thymic selection of iNKT cells?
What controls the transient inactivation of
a-Gal-A enzyme activity in DCs stimulated
with microbial products? How might the
relatively modest suppression of a-Gal-A
activity in response to microbes mediate
such a profound effect on iNKT cell activa-
tion? Do the relevant self-antigens that
accumulate in Fabry mice contribute to
other pathological conditions that are
influenced by iNKT cells? To what extent,
if at all, is this pathway conserved in
humans? Providing answers to these
questions will likely keep iNKT cell biolo-
gists busy for the coming years.Immunity 33REFERENCES
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The interaction between different transcriptional pathways in CD8+ T cell memory remains incompletely
understood. In this issue, Zhou et al. (2010) demonstrate an important role for T cell factor 1 in regulating
CD8+ T cell memory via control of a second transcription factor, Eomesodermin.There are clear parallels between the de-
velopment of adaptive immune responses
and other developmental systems. The
Wnt-b-catenin pathway is important in
many of these development processes.
Although canonical Wnt signaling has a
role in thymic development and has been
reported to influence CD8+ T cell memory(Zhao et al., 2010), precisely how this
morphogenic signaling pathway is linked
to the transcriptional regulation of T cell
memory has remained unclear. Normally,
in the absence of Wnt ligands, b-catenin
is sequestered and rapidly degraded in
the cytoplasm. Wnt signaling stabilizes
b-catenin, allowing translocation to thenucleus and interaction with T cell factor 1
(TCF-1). b-catenin displaces TLE1, aGrou-
cho family corepressor bound to TCF-1,
converting the repressive TCF-1-TLE1
complex into a TCF-1-b-catenin transcrip-
tional activator (MacDonald et al., 2009).
In this issue, Zhou et al. (2010)
demonstrate that TCF-1 activation by, August 27, 2010 ª2010 Elsevier Inc. 145
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Figure 1. Development of the CD8 T Cell Response to Viral Infection
Upon activation, naive CD8+ T cells proliferate and differentiate into two subsets: terminal effectors (red) andmemory precursors (yellow). While terminal effectors
undergo cell death, memory precursors mature into Tem-like cells (green) as they enter the memory phase. Over time, these Tem cells further differentiate into
Tcm cells (blue), which are efficiently maintained by IL-7- and IL-15-driven self-renewal. TCF-1 might regulate this developmental process during (1) early lineage
decisions, (2) survival during the contraction phase, (3) differentiation from Tem to Tcm cells, or (4) self-renewal of Tcm cells.
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PreviewsWnt-b-catenin signaling is a key event in
the transcriptional induction of Eomes, a
transcription factor involved in CD8+
T cell memory (Intlekofer et al., 2005).
Although some alterations in the primary
CD8+ T cell response to Listeria monocy-
togenes were observed, a major effect of
TCF-1 deficiency was the failure to
acquire canonical memory CD8+ T cells
properties, notably homeostatic mainte-
nance. This defect was more severe in
lymphoid organs, and TCF-1-deficient
memory CD8+ T cells remained CD62Llo
and CCR7lo, consistent with poor devel-
opment or maintenance of ‘‘central mem-
ory’’ CD8+ T (Tcm) cells. Without TCF-1,
expression of IL-15Rb (CD122) was
reduced and TCF-1-deficient memory
CD8+ T cells had defective homeostatic
proliferation consistent with impaired
IL-15 responsiveness. Eomes has been
previously implicated in CD8+ T cell
memory via CD122 expression (Intlekofer
et al., 2005). Zhou et al. (2010) now show
that Eomes expression was markedly
reduced in the absence of TCF-1. Retro-
viral overexpression of Eomes in TCF-1-
deficient cells restored CD122 expression
and improved survival, demonstrating
that TCF-1-dependent expression of
Eomes contributed to memory CD8+
T cell maintenance.146 Immunity 33, August 27, 2010 ª2010 ElsOne interesting set of observations
from this work and other recent studies
(Jeannet et al., 2010) is the potential role
of TCF-1 at different points during CD8+
T cell activation and differentiation. Nor-
mally, after acute infection, distinct stages
of memory CD8+ T cell differentiation
exist. After initial stimulation, naive CD8+
T cells become activated, proliferate,
acquire effector functions, and give rise
to two subsets of effector CD8+ T cells.
KLRG1hiCD127lo CD8+ T cells are potent
effector CD8+ T cells but are terminally
differentiated. These cells cannot give
rise to self-renewing, stable populations
of memory CD8+ T cells and their
numbers decline rapidly during contrac-
tion, but then more slowly in the early
memory phase (Joshi et al., 2007). These
cells also proliferate poorly upon rechal-
lenge (Kaech and Wherry, 2007). In con-
trast, KLRG1loCD127hi CD8+ T cells can
further differentiate into long-lived, home-
ostatically maintained memory CD8+
T cells. Initially, the memory population
formed by the KLRG1loCD127hi memory
precursors is CD62Llo and resembles an
effector memory T (Tem) cell-like popula-
tion. Over time, these Tem cells can
give rise to CD62Lhi Tcm-like cells
capable of robust proliferative expansion
after rechallenge (Kaech and Wherry,evier Inc.2007). It is also these Tcm cells that can
efficiently use IL-7 and IL-15 and undergo
homeostatic proliferation (Kaech and
Wherry, 2007). Although several other
populations of memory CD8+ T cells
might also exist, the circulating pool of
pathogen-specific CD8+ T cells present
during the first several months after infec-
tion is composed of mainly three subpop-
ulations: residual terminally differentiated
KLRG1hi CD8+ T cells, KLRG1lo Tem cells
derived from memory precursors, and
Tcm cells derived from Tem cells
(Figure 1).
Zhou et al. (2010) demonstrated that
without TCF-1, lower numbers of CD62Lhi
Tcm cells were formed. In addition, the
TCF-1-deficient CD8+ T cells expanded
poorly after rechallenge. Impaired recall
responses in TCF-1-deficient mice were
also recently reported by Jeannet et al.
(2010). These observations, together
with the defective homeostatic mainte-
nance reported by Zhou et al. (2010), are
consistent with defects in Tcm cells in
the absence of TCF-1. Conversely, both
Zhou et al. (2010) and Jeannet et al.
(2010) report a major increase in KLRG1hi
effector CD8+ T cells (though the details
differed slightly depending on the infec-
tion). These early alterations in the
subsets of effector CD8+ T cells and the
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Previewslater defects in Tcm cells suggest that
TCF-1 could impact memory CD8+ T cell
differentiation at several stages (Figure 1).
First, TCF-1might be important during the
first several days after infection when
early fate decisions between terminal
effectors and memory precursors are
made. TCF-1 is highly expressed in naive
CD8+ T cells, but expression decreases
during the first 5 days after infection
(Zhao et al., 2010). Thus, the increase in
KLRG1hi effector cells in the absence of
TCF-1 suggests that TCF-1 favors the
generation of memory precursors at
the expense of terminally differentiated
effector CD8+ T cells. Such a shift could
explain the defective recall responses in
the absence of TCF-1. However, KLRG1hi
effector CD8+ T cells survive poorly into
the memory phase in the absence of
IL-15 signals (Joshi et al., 2007). Presum-
ably, the ability to use IL-15 would be
defective in TCF-1-deficient effector
CD8+ T cells given the impact of TCF-1
on Eomes-dependent CD122 expression
in memory CD8+ T cells, though this issue
warrants further investigation. However, it
is unlikely that the impact of TCF-1 defi-
ciency on recall responses is entirely
due to defective IL-15 signaling, because
recall responses are intact in Il15/mice
(Becker et al., 2002). A role for changes
in IL-2 signaling via CD122, which can
impact CD8+ T cell memory, has also
not been ruled out. In addition, although
increasing Eomes expression improved
survival of TCF-1-deficient memory
CD8+ T cells, it is unclear: (1) whether
retroviral expression of Eomes in effector
cells would restore the normal distribution
of effector subsets, (2) whether TCF-1 has
additional Eomes-independent functions
in effector CD8+ T cell lineage decisions,
or (3) whether Eomes expression can
be controlled in a TCF-1-independent
manner at some stages.
A second way TCF-1 deficiency could
impact the CD8+ T cell memory is via
differential survival. Although KLRG1lo
memory CD8+ T cells appear less depen-
dent on IL-15 to enter the memory pool
compared the KLRG1hi subset (Joshi
et al., 2007), it will be interesting to
examine selective survival of TCF-1-defi-
cient effector subpopulations during this
transition. It is also possible that TCF-1has a role in the establishment of the
Tcm cell pool because either Tcm (or
Tem) cells fail to survive in the absence
of CD122, or because TCF-1 is important
for Tem/Tcm cell conversion. This latter
possibility is intriguing, because little is
known about the transcriptional control
of Tem/Tcm cell differentiation. Finally,
it will be interesting to determine whether
Wnt ligand availability is greater in anat-
omical locations associated with early
fate decision checkpoints (e.g., in con-
tact with dendritic cells) and/or memory
CD8+ T cell homeostasis (e.g., the bone
marrow).
Zhou et al. (2010) demonstrate that
TCF-1 binds to the regulatory regions of
the Eomes gene. In the presence of Wnt
signaling and b-catenin activation, TCF-1
induces Eomes expression. However,
TCR signaling might disrupt Wnt signaling
via TCF-1 downregulation. As antigen is
cleared, TCF-1 expression rises and
b-catenin-TCF-1 complexes can again
form. It is interesting that Zhou et al.
(2010) show both the corepressor TLE1
and b-catenin present with TCF-1 at the
regulatory regions of the Eomes gene in
naive CD8+ T cells. Because a deficiency
in TCF-1 eliminates both activating TCF-
1-b-catenin and repressive TCF-1-TLE1
complexes, it will be important in the
future to determine whether TCF-1-
dependent transcriptional repression also
impacts effector and/or memory CD8+
T cell differentiation. In addition, the
precise role of TCF-1 in the regulating
Eomes before, during, and after activa-
tion, where Eomes cooperates with
T-bet and Runx3 (Cruz-Guilloty et al.,
2009), will be exciting to unravel.
Cascades of interdependent transcrip-
tion factor pathways are central to many
developmental pathways including hema-
tapoiesis (Laslo et al., 2006). The identifi-
cation of a key role for TCF-1 in CD8+
T cell memory highlights how this tran-
scription factor can toggle between
different functional states based on the
presence of b-catenin and can regulate
a second transcription factor important
for CD8+ T cell memory (Eomes). These
data indicate that defining the networks
of overlapping transcriptional modules
controlling CD8+ T cell memory will be
complex and will depend on the applica-Immunity 33tion of genomic approaches, detailed
loss- and gain-of-function studies, and
careful consideration of the state of the
cells being analyzed. This latter point is
illustrated by the distinct functional
TCF-1 complexes that might exist in
naive, effector, memory CD8+ T cells
given the presence of different repressive
(TLE) or activating (b-catenin) cofactors.
Ultimately, of course, the goals of
such studies are to improve the ability
to manipulate immunological memory,
vaccines, and immunotherapies. Tran-
scription factors as drugable targets are
notoriously difficult. However, as illus-
trated by Zhou et al. (2010), when the
details of the upstream biological path-
ways are understood in sufficient detail,
it might be feasible to manipulate a tran-
scription factor-mediated influence on
T cell memory. As our understanding
of the transcriptional circuitry of T cell
memory improves, it should be possible
to investigate ways to apply this informa-
tion toward clinical immunomodulation.
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